Features, pricing, ratings, and pros and cons, compared head to head.
Gardiyan MDM is a commercial mobile device management tool by Gardiyan. Ivanti Neurons for MDM is a commercial mobile device management tool by Ivanti. Compare features, ratings, integrations, and community reviews side by side to find the best mobile device management fit for your security stack. Independent and vendor-neutral: we never sell rankings.
Based on our analysis of NIST CSF 2.0 coverage, core features, integrations, company size fit, here is our conclusion:
Mid-market and enterprise IT teams managing heterogeneous device fleets across multiple geographies should evaluate Gardiyan MDM for its hybrid deployment flexibility and real-time remote intervention capabilities, which let you enforce security posture without waiting for device check-in cycles. The platform's coverage of NIST PR.AA and PR.PS controls reflects solid access and platform hardening, though continuous monitoring gaps mean you'll need complementary tooling to catch behavioral anomalies that simple compliance status reports miss. This is a poor fit if your organization requires deep integration with existing SIEM platforms or needs advanced threat intelligence feeds baked into MDM; Gardiyan prioritizes device control and compliance over detection.
Mid-market and enterprise teams managing heterogeneous device fleets should pick Ivanti Neurons for MDM for its genuine multi-OS depth: iOS, Android, macOS, Windows, ChromeOS, and wearables all handled from one console with native enrollment automation via Apple Business Manager, Google Zero-Touch, and Windows AutoPilot. The platform scores well across NIST PR.AA and PR.PS, meaning access control and platform hardening are genuinely native rather than bolted on. Skip this if your priority is detection and response speed; Ivanti's strength is enrollment, configuration, and asset inventory, not anomaly hunting or incident response orchestration.
Centralized platform for managing and securing mobile devices in enterprises
Cloud-based MDM for iOS, Android, macOS, Windows, ChromeOS & watchOS devices
Access NIST CSF 2.0 data from thousands of security products via MCP to assess your stack coverage.
Access via MCPNo reviews yet
No reviews yet
Explore more tools in this category or create a security stack with your selections.
Common questions about comparing Gardiyan MDM vs Ivanti Neurons for MDM for your mobile device management needs.
Gardiyan MDM: Centralized platform for managing and securing mobile devices in enterprises. built by Gardiyan. Core capabilities include Centralized mobile device management, Remote device monitoring and control, Security configuration enforcement..
Ivanti Neurons for MDM: Cloud-based MDM for iOS, Android, macOS, Windows, ChromeOS & watchOS devices. built by Ivanti. Core capabilities include Multi-OS device management for iOS, iPadOS, watchOS, Android, macOS, ChromeOS, Windows, and VR/XR, Over-the-air device provisioning and configuration, Automated device enrollment via Apple Business Manager, Google Zero-Touch, and Windows AutoPilot..
Both serve the Mobile Device Management market but differ in approach, feature depth, and target audience.
Gardiyan MDM differentiates with Centralized mobile device management, Remote device monitoring and control, Security configuration enforcement. Ivanti Neurons for MDM differentiates with Multi-OS device management for iOS, iPadOS, watchOS, Android, macOS, ChromeOS, Windows, and VR/XR, Over-the-air device provisioning and configuration, Automated device enrollment via Apple Business Manager, Google Zero-Touch, and Windows AutoPilot.
Gardiyan MDM is developed by Gardiyan. Ivanti Neurons for MDM is developed by Ivanti. Vendor maturity, funding stage, and team size can be important factors when evaluating long-term viability and support quality.
Gardiyan MDM and Ivanti Neurons for MDM serve similar Mobile Device Management use cases: both are Mobile Device Management tools. Review the feature comparison above to determine which fits your requirements.
Get strategic cybersecurity insights in your inbox